Log In
BCIQ
Print this Print this
 

IMAB362

Also known as: claudiximab

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
Description mAb targeting cell surface antigen CLND18.2
Molecular Target CLND18.2
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,395.6M

$459.4M

$936.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/21/2016

$1,395.6M

$459.4M

$936.2M

Get a free BioCentury trial today